The on- and off-target effects of morphine in acute coronary syndrome: A narrative review

Cian P. Mccarthy, Kieran V. Mullins, Sunjeet S. Sidhu, Steven P. Schulman, John W. Mcevoy

Research output: Contribution to journalReview articlepeer-review

Abstract

With potent analgesic properties, perceived hemodynamic benefits and limited alternatives, morphine is the analgesic mainstay for patients with nitrate resistant chest pain due to acute Myocardial Infarction (MI). However, observational data suggest that morphine administration during MI may have negative consequences. While vomiting, hypotension and respiratory depression are established side effects, recent reports have demonstrated attenuated and delayed oral anti-platelet agent absorption, as well as suboptimal reperfusion after MI, all of which may translate into adverse cardiovascular outcomes. These data have resulted in reduced support for morphine in recent European and U.S. clinical practice guidelines for MI; despite the absence of any prospective randomized outcomes trials addressing this question. As such, randomized trials are now necessary to confirm whether or not morphine, which is administered in up to 30% of MI cases, causes adverse clinical outcomes in these patients. However, given that placebo-controlled randomized trial designs evaluating morphine in MI are limited by an ethical requirement for appropriate analgesia, alternative investigational approaches may be necessary. In this article we review the updated evidence for morphine in MI and outline novel strategies that may facilitate future investigation of this clinical dilemma.

Original languageEnglish (US)
Pages (from-to)114-121
Number of pages8
JournalAmerican heart journal
Volume176
DOIs
StatePublished - Jun 1 2016

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The on- and off-target effects of morphine in acute coronary syndrome: A narrative review'. Together they form a unique fingerprint.

Cite this